MesomiR 1, A Phase I study of TargomiRs as 2nd or 3rd line treatment for patients with recurrent MPM and NSCLC
The ADRI ran an early stage clinical trial of a new approach to therapy for selected patients with malignant pleural mesothelioma or non-small cell lung cancer. The trial aim was to test optimal dose of TargomiRs, an experimental medication consisting of ADRI’s microRNA mimic encapsulated in EnGeneIC’s targeted EDV(TM) nanocells, and was carried out at three Sydney hospitals: Concord Repatriation General Hospital, Royal Prince Alfred Hospital/ Lifehouse, and Royal North Shore Hospital.
The results of this clinical trial was published in Lancet Oncology on the 1st September 2017.
Quality of life in patients with Mesothelioma
The ADRI is running a study investigating ‘quality of life’ in patients diagnosed with mesothelioma. While we are aware that there is a high symptom burden in patients suffering from mesothelioma, we have little information on ‘quality of life’ in people living with this disease. By using questionnaires we try to get a more accurate picture of the impact of the disease and treatment on ‘quality of life’. Our study will look at how quality of life changes over time, and the impact of different types of treatment. We are also interested in learning more about psychological needs (anxiety and depression), and whether people are actually receiving the care that they need. How quality of life relates to other issues such as nutrition and functional (physical) ability, and relationships with inflammatory markers will also be studied in select hospitals.